Chris Hani Baragwanath Academic Hospital
Johannesburg, GP, 2192, South Africa
NCT Number: NCT05264662
Pertussis (also known as whooping cough) is a highly contagious, vaccine-preventable respiratory tract disease, caused by the bacteria Bordetella pertussis. It can affect people of all ages, however young unimmunised or partially immunised infants are the most vulnerable group with the highest rates of complications and death. Recent surveillance data and an increase in the number of pertussis outbreaks being reported nationally, indicate an increase in the incidence of pertussis disease in South Africa.To date there is no data on the effect of vaccinating HIV-infected pregnant women with pertussis-containing vaccines, although there is no reason to think that vaccinating these women would be harmful for them or their foetus. The knowledge gaps on the immunogenicity, safety and VE of pertussis vaccination of HIV-infected pregnant women should be addressed. Adacel which is a registered and licensed vaccine manufactured by Sanofi Pasteur, will be tested in this study.
Looking for future studies?
Notify Me18 year–39 year
Female
Interventional
Phase 4
Johannesburg, GP, 2192, South Africa
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administer Adacel to hiv infected and hiv uninfected pregnant mothers
Time frame: 24 months
To measure antibody responses to all Tdap-IPV antigens (diphtheria, tetanus, PT, FHA, PRN, FIM and polioviruses 1, 2 and 3) in HIV-infected compared with HIV-uninfected pregnant women before and one month after Adacel vaccination.
Time frame: 24 months
To measure antibody responses to all Tdap-IPV and Hexavalent antigens (diphtheria, tetanus, PT, FHA, PRN, FIM, Haemophilus influenzae type-b polyribosyl ribitol phosphate [PRP], polioviruses 1, 2 and 3, and hepatitis B) testing in infants born to mothers who received Adacel during pregnancy and those born to mothers not vaccinated, stratified by maternal HIV status.
Time frame: 24 months
To compare the transplacental antibody transfer ratio of all Tdap-IPV antigens to newborns from HIV-infected mothers and those born to HIV-uninfected mothers vaccinated with Adacel during pregnancy.
Time frame: 24 months
Number of HIV-infected and HIV-uninfected pregnant women with treatment-related adverse events.
Farzanah Laher
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02432430
Behavior, Blood-Borne Infections
View Trial DetailsNCT06891872
Chickenpox, DNA Virus Infections
Chongqing, China
View Trial DetailsNCT05136599
Bacterial Infections, Bacterial Infections and Mycoses
Halifax, Nova Scotia, Canada
View Trial DetailsNCT07444502
Actinomycetales Infections, Bacterial Infections
Bangkok, Thailand
View Trial Details